하이텍팜
Financials
Valuation Metrics
하이텍팜's Market Cap is ₩1154B. At end of 2025 it was ₩1278B. Ranked #1138 of 2,436 in KR market (top 47%), #587 of 1,649 on KOSDAQ (top 36%), #133 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 115.37B KRW | KR#1,138/2,436 Sec#133/234 |
| Revenue | 69.05B KRW | KR#1,620/2,436 Sec#106/234 |
| Net Income | 9.02B KRW | KR#937/2,436 Sec#60/234 |
| Total Assets | 145.35B KRW | KR#1,495/2,436 Sec#117/234 |
| Net Assets | 128.81B KRW | KR#1,213/2,436 Sec#97/234 |
| Employees | 125 | KR#1,458/2,436 Sec#116/234 |
| Value | ||
| P/E | 12.78x | KR#866/2,436 Sec#54/234 |
| P/B | 0.90x | KR#1,394/2,436 Sec#87/234 |
| P/S | 1.67x | KR#1,730/2,436 Sec#96/234 |
| EV/EBITDA | 11.67x | KR#688/2,436 Sec#34/234 |
| FCF Yield | 13.09% | KR#512/2,436 Sec#16/234 |
| Profitability | ||
| ROE | 7.01% | KR#790/2,436 Sec#57/234 |
| ROA | 6.21% | KR#505/2,436 Sec#37/234 |
| Op. Margin | 13.32% | KR#332/2,436 Sec#30/234 |
| Revenue Growth | -7.42% | KR#1,787/2,436 Sec#165/234 |
| Earnings Growth | -112.23% | KR#1,394/2,436 Sec#90/234 |
| Financial Health | ||
| Debt Ratio | 112.84% | KR#502/2,436 Sec#67/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | 15.10B KRW | KR#595/2,436 Sec#31/234 |
| Cash | 7.98B KRW | KR#1,798/2,436 Sec#154/234 |
| Current Ratio | 4.62x | KR#331/2,436 Sec#62/234 |
| Net Debt/EBITDA | -0.87x | KR#492/2,436 Sec#27/234 |
| Dividend | ||
| Div. Yield | 1.43% | KR#1,049/2,436 Sec#58/234 |
| Div. Growth | 50.00% | KR#218/2,436 Sec#8/234 |
| Performance | ||
| 1Y Return | -14.30% | KR#1,091/2,436 Sec#81/234 |
| 1M Return | -14.16% | KR#1,934/2,436 Sec#183/234 |
| From 52W High | -56.60% | KR#1,502/2,436 Sec#123/234 |
| 1Y MDD | -60.16% | KR#1,420/2,436 Sec#112/234 |
| Trading | ||
| Volume | 10,916 shares | KR#1,954/2,436 Sec#192/234 |
| Foreign Own. | 46.88% | KR#36/2,436 Sec#3/234 |
| Per Share | ||
| EPS | 849 KRW | KR#693/2,436 Sec#48/234 |
| BPS | 12,115 KRW | KR#817/2,436 Sec#59/234 |
Company Info
Hitech Pharm, established in 1998 and headquartered in Chungju, Chungcheongbuk-do, is a specialized enterprise for antibiotic raw pharmaceutical ingredients, listed on KOSDAQ in 2010. It primarily produces Carbapenem-class antibiotics, with main products Imipenem and Ertapenem, which are high-priced due to their high antibacterial activity, and largely exported to Europe and Asia. The company possesses Carbapenem-class antibiotic technology achieving higher yields and lower impurities than competitors, fostering its growth in the global market via next-generation production plants.